6 TECH OUTLOOKMARCH-APRIL, 2017Copyright © 2017 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.MARCH-APRIL, 2017Mailing AddressValleyMedia Inc.44790 S. Grimmer Blvd Suite 202, Fremont, CA 94538T:510 230 0395, F:510-894-8405 MARCH-APRIL, 2017, Vol 03 - 03 Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Editor-in-ChiefStacey SmithEditorial StaffSalesVisualizerMatt RyderChetan.NAaron Pierce Ava GarciaJenna VegasJoshua ParkerJustin SmithMelissa ReaktinwalteClinical Trial Management SpecialRichard Watson richard@pharmatechoutlook.comEditorialStacey Smith Editor-in-ChiefFrom being late adopters of disruptive technologies, the pharmaceutical and life sciences industry has come to a phase where in they are at the luxury to choose from a plethora of solution providers, with multiple innovations at their disposal. Driving factors for this exponential increase in innovation include a rise in the R&D activities by various pharma and biopharma companies, growing application of software solutions in medical trials, and rising government funding for promoting clinical research programs. And in increasingly digital environments, successful trials require collaboration, digital knowledge and patient engagement. As such, the CTMS market is projected to grow at a CAGR of 11.5 percent in the next four years. Looking at the challenges ahead for the vertical, security issues, lack of qualified labor and high cost of customized CTMS are some of the reasons hindering the growth of the market. Just as the vertical is subject to technological advancement, it may not be easily feasible to retune processes once they are in place given the generally long durations of research. CIOs thus have to make informed decisions from the get-go.Meanwhile, regulatory pressures, along with the rising cost of drug development have given rise to the trend of outsourcing clinical research. This in turn is having ripple effects in the industry. Clinical Research Orgainzations have expanded their capabilities to include project management, study design and analytics to name a few. The sector is en route to achieving standard defining initiatives that bridge clinical development and commercialization just as it would prove to be more efficient in terms of cost and time to market. In this scenario, curating content for this edition has been a dive into exploring a plethora of service providers, changing trends, need of the hour and a glimpse into how the future of eClinical Trial Management would turn out to be. We hope the valuable insights from industry thought-leaders and the innovative solutions from leading as well as emerging companies featured in this edition will help you in making informed decisions in your eClinical Trial Management endeavors.Bridging Clinical Developments and CommercializationTECH OUTLOOKTECH OUTLOOK*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staff
< Page 5 | Page 7 >